18:52:56 EDT Sun 07 Aug 2022
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Avicanna Inc
Symbol AVCN
Shares Issued 41,271,574
Close 2021-06-11 C$ 1.08
Recent Sedar Documents

Avicanna to file 2020, Q1, Q2 2021 results in 75 days

2021-06-30 19:03 ET - News Release

An anonymous director reports

AVICANNA FINANCIAL STATEMENT UPDATE

Avicanna Inc.'s audit is continuing, and the company expects to file the following periodic disclosure documents within the next 60 to 75 days:

  • Audited annual financial statements for the year ended Dec. 31, 2020;
  • Management's discussion and analysis relating to the audited annual financial statements for the year ended Dec. 31, 2020;
  • Annual information form for the year ended Dec. 31, 2020;
  • Interim financial statements for the period ended March 31, 2021;
  • Management's discussion and analysis relating to the interim financial statements for the period ended March 31, 2021;
  • Interim financial statements for the period ended June 30, 2021;
  • Management's discussion and analysis relating to the interim financial statements for the period ended June 30, 2021;
  • Certification of the foregoing filings as required by National Instrument 52-109 (Certification of Disclosure in Issuers' Annual and Interim Filings).

The company continues to operate normally and achieve operational milestones, as described in the company's news release on June 24, 2021.

Pursuant to the company's news release on June 11, 2021, despite the cease trade order issued by the Ontario Securities Commission, a beneficial securityholder of the company who is not, and was not, at the date of the CTO, an insider or control person of the company, may sell securities of the company acquired before the date of the CTO if the sale is made through an investment dealer registered in a jurisdiction of Canada on a foreign organized regulated market, as defined in Section 1.1 of the Universal Market Integrity Rules of the Investment Industry Regulatory Organization of Canada. Holders of Avicanna securities are urged to consult with their own investment advisers or legal counsel about the implications of the CTO.

About Avicanna Inc.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical and pharmaceutical market segments.

We seek Safe Harbor.

© 2022 Canjex Publishing Ltd. All rights reserved.